What is the 13F Pro Quality Score for INAB?

13F Pro ranks IN8BIO, INC. (INAB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INAB's current score at https://13fpro.ai/research/INAB (free sign-up required for the full ranking).

Where does 13F Pro source INAB data?

All IN8BIO, INC. fundamentals and ownership data come directly from SEC EDGAR. IN8BIO, INC. files with the SEC under CIK 1740279. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INAB in?

IN8BIO, INC. (INAB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INAB research updated on 13F Pro?

INAB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IN8BIO, INC.(INAB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1740279 INAB stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

INAB Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IN8BIO, INC. (INAB), a Healthcare sector company. INAB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), IN8BIO, INC. reports net income of $-5.1M, free cash flow of $-4.9M. Top institutional holders of INAB by reported 13-F value include Alyeska Investment Group, L.P., FRANKLIN RESOURCES, 683 Capital Management,, based on the most recent SEC filings. INAB trades on the Nasdaq exchange and files with the SEC under CIK 1740279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IN8BIO, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.1M

Free Cash Flow

Q1 2026

$-4.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+36.1% YoY

$-19.4MFY 2025

FY21 $-14.7MFY22 $-28.5MFY24 $-30.4MFY25 $-19.4M

Operating Income

+36.1% YoY

$-19.4MFY 2025

FY21 $-14.7MFY22 $-28.5MFY24 $-30.4MFY25 $-19.4M

EPS (Diluted)

+74.0% YoY

$-4.44FY 2025

FY21 $-1.47FY22 $-1.36FY24 $-17.05FY25 $-4.44

Total Assets

+54.1% YoY

$32.3MFY 2025

FY21 $42.2MFY22 $33.0MFY24 $20.9MFY25 $32.3M

Op. Cash Flow

+47.4% YoY

$-12.7MFY 2025

FY21 $-13.5MFY22 $-24.1MFY24 $-24.1MFY25 $-12.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Net Income	$-19.4M +36.1%	$-30.4M -6.7%	$-28.5M -94.6%	$-14.7M -71.2%	$-8.6M
Operating Income	$-19.4M +36.1%	$-30.4M -6.7%	$-28.5M -94.6%	$-14.7M -71.2%	$-8.6M
EPS (Diluted)	$-4.44 +74.0%	$-17.05 -1153.7%	$-1.36 +7.5%	$-1.47	—
Total Assets	$32.3M +54.1%	$20.9M -36.6%	$33.0M -21.8%	$42.2M +101.9%	$20.9M
Operating Cash Flow	$-12.7M +47.4%	$-24.1M -0.1%	$-24.1M -78.6%	$-13.5M -89.4%	$-7.1M

AI Insight: INAB Financial Trends

IN8BIO's quarterly losses have improved from $9M to $4M-$5M range, but operating cash flow volatility and lack of revenue remain concerns.

• Net losses improved from $9M in Q2 2024 to $4M-$5M range in recent quarters.

• Operating cash flow improved from $-6M in Q2 2024 to $-2M in Q4 2025.

• Equity strengthened to $28M in Q4 2025 from $14M in Q2 2024.

⚠ Operating cash flow deteriorated from $-2M in Q4 2025 to $-5M in Q1 2026.

⚠ No revenue reported across all quarters — company remains pre-commercial.

AI Insight: INAB Ratio Trends

IN8BIO's ROE losses narrowed dramatically from -170.2% in Q4 2024 to -71.7% in Q4 2025 before widening again to -89.4% in Q1 2026.

• ROE improved significantly from -170.2% in Q4 2024 to -71.7% in Q4 2025, showing consistent quarterly improvement through mid-2025.

• ROA losses also narrowed from -91.9% in Q3 2025 to -61.2% in Q4 2025 before deteriorating to -77.5% in Q1 2026.

⚠ ROE and ROIC both worsened in Q1 2026 to -89.4% after reaching their best levels in Q4 2025 at -71.7%.

⚠ Operating margin and net profit margin data remain unavailable across all periods, limiting visibility into operational efficiency trends.

Get alerted when INAB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IN8BIO, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INAB

Alyeska Investment Group, L.P.
$1.4M944,319 sh
FRANKLIN RESOURCES INC
$1.4M914,531 sh
683 Capital Management, LLC
$1.1M724,637 sh
Stonepine Capital Management, LLC
$981.9K663,412 sh
BIOS Capital Management, LP
$248.4K167,805 sh
GEODE CAPITAL MANAGEMENT, LLC
$127.6K86,239 sh
CAPTRUST FINANCIAL ADVISORS
$49.3K33,295 sh
OPPENHEIMER & CO INC
$35.6K24,033 sh
Texas Capital Bank Wealth Management Services Inc
$35.1K23,750 sh
NORTHERN TRUST CORP
$30.3K20,440 sh

Fund	Value	Shares
Alyeska Investment Group, L.P.	$1.4M	944,319
FRANKLIN RESOURCES INC	$1.4M	914,531
683 Capital Management, LLC	$1.1M	724,637
Stonepine Capital Management, LLC	$981.9K	663,412
BIOS Capital Management, LP	$248.4K	167,805
GEODE CAPITAL MANAGEMENT, LLC	$127.6K	86,239
CAPTRUST FINANCIAL ADVISORS	$49.3K	33,295
OPPENHEIMER & CO INC	$35.6K	24,033
Texas Capital Bank Wealth Management Services Inc	$35.1K	23,750
NORTHERN TRUST CORP	$30.3K	20,440

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INAB on your watchlist

Track score changes the day IN8BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INAB a good stock to buy?

13F Pro's AI-powered analysis of IN8BIO, INC. (INAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INAB are available on the INAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INAB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IN8BIO, INC.'s investment landscape.